245 related articles for article (PubMed ID: 32264742)
21. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
22. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
[TBL] [Abstract][Full Text] [Related]
23. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.
Xia J; Huang R; Chen Y; Liu Y; Wang J; Yan X; Zhang Z; Wu C
Aliment Pharmacol Ther; 2020 Jun; 51(11):1180-1187. PubMed ID: 32363582
[TBL] [Abstract][Full Text] [Related]
24. Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus.
Wang H; Cao J; Lai X
Molecules; 2016 Dec; 22(1):. PubMed ID: 28036035
[TBL] [Abstract][Full Text] [Related]
25. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus.
Nishino A; Katsumata Y; Kawasumi H; Hirahara S; Kawaguchi Y; Yamanaka H
Lupus; 2019 Jul; 28(8):986-994. PubMed ID: 31246559
[TBL] [Abstract][Full Text] [Related]
27. Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: A monocentric cross-sectional study.
Wu X; Xu L; Cheng Q; Nie L; Zhang S; Du Y; Xue J
Respir Med; 2020 May; 166():105948. PubMed ID: 32250876
[TBL] [Abstract][Full Text] [Related]
28. Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.
Zhang J; Zhang H; Luo Y
Med Sci Monit; 2019 Feb; 25():1275-1282. PubMed ID: 30771277
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
[TBL] [Abstract][Full Text] [Related]
30. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Terai S
Int J Med Sci; 2017; 14(5):403-411. PubMed ID: 28539815
[No Abstract] [Full Text] [Related]
31. Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Up-Regulation Capacity of Post-Activated Lupus B Cells.
Stefanski AL; Wiedemann A; Reiter K; Hiepe F; Lino AC; Dörner T
Arthritis Rheumatol; 2019 Sep; 71(9):1539-1544. PubMed ID: 30919595
[TBL] [Abstract][Full Text] [Related]
32. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
[TBL] [Abstract][Full Text] [Related]
33. Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus.
Liu MF; Weng CT; Weng MY
J Biomed Biotechnol; 2009; 2009():406136. PubMed ID: 19759858
[TBL] [Abstract][Full Text] [Related]
34. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
35. Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis.
Chen H; Peng Q; Yang H; Yin L; Shi J; Zhang Y; Wang G
J Rheumatol; 2018 Jun; 45(6):835-840. PubMed ID: 29419471
[TBL] [Abstract][Full Text] [Related]
36. PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus.
Luo Q; Huang Z; Ye J; Deng Y; Fang L; Li X; Guo Y; Jiang H; Ju B; Huang Q; Li J
Arthritis Res Ther; 2016 Feb; 18():47. PubMed ID: 26867643
[TBL] [Abstract][Full Text] [Related]
37. Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients.
Shi H; Ye J; Teng J; Yin Y; Hu Q; Wu X; Liu H; Cheng X; Su Y; Liu M; Gu J; Lu T; Chen H; Zheng H; Sun Y; Yang C
Arthritis Res Ther; 2017 Mar; 19(1):52. PubMed ID: 28274252
[TBL] [Abstract][Full Text] [Related]
38. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
39. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus.
Davas EM; Tsirogianni A; Kappou I; Karamitsos D; Economidou I; Dantis PC
Clin Rheumatol; 1999; 18(1):17-22. PubMed ID: 10088943
[TBL] [Abstract][Full Text] [Related]
40. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
